Wegovy dose per click: what the chart actually tells you

What a 'dose per click' chart means for a fixed-dose pen like Wegovy

Wegovy pens are not dial-up devices. Unlike some insulin pens where the patient dials a number of units, each Wegovy pen is factory-set to deliver one specific dose in a single injection. You press the button once, the full dose is delivered, and the pen locks. There are no clicks to count, no dial to set, no partial doses.

So when people search for a Wegovy dose-per-click chart, what they are usually looking for is a clear breakdown of what each pen in the titration sequence actually contains, how the 0.25 mg starter pen differs from the 1.0 mg mid-titration pen, and so on up to the 2.4 mg maintenance pen. That is genuinely useful information, and it is exactly what this page covers.

It is also worth knowing that Wegovy pens are single-use. Each pen is used once, for one weekly injection, then disposed of safely. If you are moving between dose steps, your prescriber will issue a prescription for the next pen strength, you do not adjust the pen you already have. For a clear breakdown of what each dose level looks like in practice, the Wegovy doses overview sets out the full picture.

The MHRA-approved 7.2 mg dose introduced in early 2026 adds a sixth step at the top of the schedule, initially supplied as three 2.4 mg pens administered weekly; a dedicated single-dose 7.2 mg pen received MHRA approval on 14 April 2026. That step is relevant only for patients on a specific clinical pathway and prescribed accordingly.

The five-step titration schedule and what each pen delivers

The standard Wegovy titration pathway, as licensed in the UK and described in the NICE semaglutide appraisal (TA875), moves through five dose levels. Each step is typically held for approximately four weeks before the prescriber considers moving up, though the pace is guided by tolerability, not a fixed calendar.

Step one is 0.25 mg per week. This is a tolerability phase, the pen's job at this stage is to let your system adjust to semaglutide before any meaningful appetite effect is expected. Step two is 0.5 mg. Steps three and four are 1.0 mg and 1.7 mg respectively. Step five, the standard maintenance dose, is 2.4 mg per week.

Each pen is physically distinct: colour-coded and labelled with its dose. You cannot accidentally use a 2.4 mg pen when a 0.25 mg pen has been prescribed, the dose is printed clearly on the device and confirmed in the packaging. If you want a dose-level-by-dose-level breakdown of the 0.5 mg pen specifically, the 0.5 mg pen guide goes into detail on that step, and similar detail for the 1.7 mg step is in the 1.7 mg pen guide.

One practical note: if your prescription arrives just before a bank holiday or you are travelling, factor in that a change in dose step requires a new prescription. Planning ahead (even just checking your supply a week before a holiday) avoids a gap. Missed doses and timing questions belong with your prescriber, not guesswork.

Why the evidence behind the titration schedule matters

The step-wise schedule is not arbitrary. It was established through the STEP clinical trial programme. In STEP 1, published in the New England Journal of Medicine, adults with obesity using semaglutide 2.4 mg weekly achieved an average body-weight reduction of around 15% over 68 weeks alongside lifestyle support, a result that informed NICE's recommendation. The lower starting doses are the scaffolding that made that outcome possible: they reduce the gastrointestinal side effects that are most likely to cause people to stop treatment early.

Nausea, loose stools and reduced appetite are most noticeable in the early steps and typically settle as the body adapts. Jumping straight to a higher dose would not accelerate results; it would most likely increase side effects without improving outcomes. The titration chart, in other words, is a clinical tool backed by trial design, not a ladder to climb as fast as possible.

Questions about side effects or how this medicine sits alongside other conditions are worth raising at your consultation. The Wegovy overview covers the broader clinical picture, including who the medicine is licensed for in the UK and what the evidence shows for longer-term weight management.

Reading any Wegovy click chart alongside clinical guidance

Charts and visual references circulate online, often created by pharmacies or patient communities to make the titration schedule easier to follow. They can be helpful as quick references. The caution is this: a chart tells you what a pen contains; it does not tell you whether that dose is right for you at this point in your treatment.

Decisions about moving to the next dose step, staying longer at a current one, or pausing treatment belong with a prescriber who knows your history. The same applies to the 2.4 mg maintenance dose, some patients do well at 1.7 mg, and the clinical goal is sustained, safe progress rather than reaching the highest dose.

If you are comparing costs at different dose steps, the Wegovy cost context page explains how UK private pricing works and what a legitimate price should include. For the 2.4 mg pen specifically, the 2.4 mg pen guide and the 1.0 mg pen guide break down those steps in more detail.

Wegovy is a prescription-only medicine. Every prescription at nume is reviewed by a GPhC-registered prescriber (a real clinician) before anything is issued or dispensed. If you are ready to find out whether you are clinically suitable, you can start your free consultation and receive a same-day clinical review.